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Abdominal aortic aneurysms (AAAs) are focal dilations of the aorta that develop from
degenerative changes in the media and adventitia of the vessel. Ruptured AAAs have a
mortality of up to 85%, thus it is important to identify patients with AAA at increased
risk for rupture who would benefit from increased surveillance and/or surgical repair.
Although the exact genetic and epigenetic mechanisms regulating AAA formation are
not completely understood, Mendelian cases of AAA, which result from pathologic var-
iants in a single gene, have helped provide a basic understanding of AAA pathophysiol-
ogy. More recently, genome wide associated studies (GWAS) have identified additional
variants, termed single nucleotide polymorphisms, in humans that may be associated
with AAAs. While some variants may be associated with AAAs and play causal roles in
aneurysm pathogenesis, it should be emphasized that the majority of SNPs do not
actually cause disease. In addition to GWAS, other studies have uncovered epigenetic
causes of disease that regulate expression of genes known to be important in AAA
pathogenesis. This review describes many of these genetic and epigenetic contributors
of AAAs, which altogether provide a deeper insight into AAA pathogenesis.
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1 | CLINICAL RELEVANCE AND
EPIDEMIOLOGY OF ABDOMINAL AORTIC
ANEURYSMS
Abdominal aortic aneurysms (AAAs) are found in ~8% of individuals
older than 65.1 As the 15th leading cause of death in patients over
65, death from AAAs is as common as that from certain cancers.2
Modifiable risk factors associated with AAA include smoking, dia-
betes, hypertension, and coronary artery disease.3 Smoking in par-
ticular results in a 5-fold increase in AAA risk.4 In contrast,
nonmodifiable factors such as family history and male gender are
also significant risk factors, suggesting a genetic component to
AAA pathogenesis.5 Twin studies also demonstrate that AAAs have
a very high degree of hereditability.6 While AAAs are found more
commonly in men, women are more likely to present with ruptured
aneurysms and rupture at smaller aortic diameters than men.7,8 This
is likely due to sex-dependent differences in aneurysm progression
and suggests a need for lower threshold for aneurysm repair in
women than current guidelines suggest.9 While AAAs are found
more frequently in men, there seems to be a greater genetic contri-
bution in women, since relatives of females have higher incidence
of AAAs.10
By far the most feared complication of AAA is rupture, which is
associated with a 65-85% risk of death.11,12 Prevalence of hospitaliza-
tion from rupture in the United States has decreased from 10 to 7 per
100 000 from 2007 to 2012, respectively, and risk of rupture
increases after age 50.2 Risk of rupture also increases substantially
with increasing vessel diameter, particularly at nonorthogonal diame-
ters between 6.5 and 7.4 cm for men (odds ratio, 3.9).11 Increased wall
stiffness, calcification, inflammation, intra-luminal thrombus, and peak
wall stress all increase rupture risk as well.13-15 Other complications
include infected, or mycotic, aneurysms, which occur in up to 3% of
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patients with AAAs and also have a 15.4% risk of rupture.16 Aortoenteric
and aortocaval fistulas, which are connections between the aorta and
intestine or inferior vena cava, respectively, are potentially catastrophic
complications of AAAs. Although they account for <1% of aortic aneu-
rysms, aortocaval fistulas are associated with nearly 55% mortality.17
The United States Preventative Task Force (USPSTF) recom-
mends one time ultrasound screening for AAA in men between
65 and 75 who have ever smoked, and women older than 65 with a
smoking history may also benefit.18 Elective AAA repair is rec-
ommended once an aneurysm reaches 5.0 cm (orthogonally) in
women, 5.5 cm in men, or grows by 0.6 to 0.8 cm per year. Depending
on age, comorbidities, and vascular anatomy, the patient may undergo
either elective endovascular aortic repair (EVAR) or open repair. Open
AAA repair is generally recommended for younger patients, individuals
with complex ilio-femoral anatomy precluding vascular access, and
patients with hostile aneurysm neck anatomy.19 In contrast, EVAR
should be considered in patients with suitable aortic anatomy, espe-
cially in older individuals who are higher risk candidates for open
repair. Importantly, challenging vascular anatomy is not an absolute
contraindication to EVAR, as several adjunctive techniques and new
devices can help facilitate access.20,21
2 | GENETIC CAUSES OF AAA
PATHOGENESIS
2.1 | Mendelian syndromes characterized by AAAs
Mendelian causes of aortic aneurysms result from single-gene muta-
tions that are often associated with additional phenotypic abnormali-
ties.22 While the majority of Mendelian forms of aortic aneurysms
affect the aortic root, ascending aorta, and thoracic aorta, some of
these same syndromes also cause AAAs.22 One commonly cited
example of Mendelian AAA is Marfan syndrome, which is an autoso-
mal dominant disorder caused by a mutation in the FBN1 gene. Muta-
tions in TGFβR1, TGFβR2, and TGFβR3 genes cause a Marfan-like
syndrome, and perturbed TGFβ signaling leads to profibrotic changes
and increased production of matrix metalloproteinases (MMPs), which
cause medial degradation.23,24 Marfan syndrome is characterized by
aneurysms of the thoracic and abdominal aorta as well as dilatation of
the aortic root.25 Although the majority of patients with Marfan syn-
drome have some family history of the disease, ~25% are de novo
cases resulting from spontaneous mutations in Marfan genes.26
Loeys-Dietz syndrome (LDS) is another Mendelian aortopathy caused
by mutations in the TGFβ signaling axis, specifically in TGFβR1,
TGFβR2, TGFβ2, TGFβ3, SMAD2, and SMAD3.27,28 Individuals with
Loeys-Dietz have several classic physical findings including vascular,
craniofacial, skeletal, and cutaneous defects. While their aneurysms
are most often found in the aortic root, up to 12% of patients have
aneurysms affecting the abdominal aorta.
In addition to Mendelian aortic syndromes caused by mutations
in TGFβ-related genes, other single-gene aortopathies include those
affecting extracellular matrix (ECM) components of the vessel wall.
These include Ehlers-Danlos syndrome, which is caused by mutations
in COL3A1, and Osteogenesis imperfecta, which results from muta-
tions in COL1A1 and COL1A2. Aneurysms affecting the proximal bra-
nches of the aortic arch, the descending thoracic aorta, and abdominal
aorta are all found in Ehlers-Danlos patients. In contrast, mostly ascend-
ing aortic arch aneurysms are seen in individuals with Osteogenesis
imperfecta, which affects the bones and connective tissues of these
patients. AAAs are also seen in patients with homocystinuria and
pseudo xanthoma elasticum, which are two autosomal recessive dis-
eases caused by mutations in the CBS and ABCC6 genes, respectively.
While aneurysms of the aortic arch and thoracic aorta are also seen in
patients with pseudo xanthoma elasticum, AAAs are more common.22
2.2 | Non-Mendelian causes of AAAs
In contrast to Mendelian aortic syndromes, non-Mendelian forms of
inheritance are more complex and characterized by variants in several
genes. Numerous AAA genetic loci have been identified, and these are
discussed below in the context of their respective genetic and molecular
pathways. This structure provides a mechanistic framework for beginning
to think about how each variant might contribute to AAA pathogenesis.
The different variants and associated loci are summarized in Table 1.
2.2.1 | Extracellular matrix
The ECM provides structural support to blood vessels and also serves
important signaling functions to surrounding cells.29 ECM turnover is
regulated by the MMP family of proteins, and several SNPs associated
with AAAs are located within genes encoding ECM components and
MMPs.30 Saracini et al genotyped over 800 patients and surveyed
variants in 12 different genes to find that MMP-3 and MMP-13 poly-
morphisms (rs3025058 and rs2252070, respectively) were signifi-
cantly associated with increased AAA risk, while rs2071307 in ELN
and rs243865 in MMP-2 trended with decreased risk.31 Separate
meta-analyses of GWAS for AAA confirmed these results and found
that rs3827066 in MMP-9 was also an AAA risk locus.32,33 Of note,
rs3827066 was also associated with altered expression of nearby
genes, PCIF1 and ZNF335.
Several mechanistic research studies have implicated MMPs in
AAA pathogenesis. For example, expression of MMP-2 and MMP-9 is
increased in human AAA tissue samples.34,35 Further, both MMP-2 and
MMP-9 knockout mice were protected from aneurysm formation com-
pared to wild-type mice in two separate AAA models.36,37 Notably, the
rs243865 minor (T) allele is located in the MMP-2 promoter and results
in decreased binding of the transcription factor Sp1 and decreased
transcription activity compared to the major (C) allele. Although this
supports the hypothesis that decreased minor allele-specific MMP-2
expression is protective against AAAs, no study to date has demon-
strated a causal relationship between rs243865 and AAAs.38
SNPs rs3025058 in MMP-3 and rs2252070 in MMP-13 are both
linked to increased AAA risk.31 Notably, MMP-3 ablation decreases
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aneurysm formation.39 rs3025058 is an insertion-deletion mutation,
and the major allele (5A) (five adenine residues, compared to six for
the minor allele [6A]) is associated with increased AAA risk and
increased MMP-3 promoter activity via an NF-KB-dependent
mechanism, lending support to the idea that increased MMP-3
expression and activity contributes to AAA pathogenesis.40-42 The
rs2252070 minor (G) allele is located within the MMP-13 promoter
and associated with increased AAA risk. While no studies exist in
endothelial, smooth muscle, fibroblasts, or other vascular cells, experi-
ments in cancer cells demonstrate that the rs2252070 major (A) allele
(which is protective) is associated with decreased MMP-13 promoter
activity, albeit already weak activity, and exhibits decreased Sp1 tran-
scription factor binding in gel shift assays.43
2.2.2 | Inflammation
Inflammation plays a key role in AAA development, and several stud-
ies have shown that CD4+ T cells accumulate within the aneurysm
wall.44 These cells secrete inflammatory cytokines that recruit effector
cells to the aneurysm site to promote the inflammatory-mediated pro-
cess. SNPs associated with AAAs in the human population have been
identified in several genes that encode some of these key inflamma-
tory components. For example, Bown et al showed that the
rs1800896 major (A) allele in the IL-10 promoter was associated with
AAA in two different studies.45,46 However, there was no significant
association between rs1800896 and AAA when the data was
corrected for risk factors known to be associated with AAA (tobacco
use, age, peripheral artery disease, and so on). In a separate study of
an equally sized Chinese population, the A allele was associated with
increased AAA formation (OR, 1.64).47
Previous in vitro studies demonstrated that the rs1800896 A
(risk) allele is associated with lower IL-10 plasma levels, which sup-
ports the idea that the A allele increases AAA risk by decreasing
expression of this anti-inflammatory cytokine.46-48 However, Bown
et al showed the opposite: higher IL-10 levels in patients with the AA
genotype after EVAR, which may be explained by a separate process
controlling the inflammatory response after surgery.45
Several studies also support an association between IL-6 signaling
and AAA pathobiology. Patients with AAA have higher circulating IL-6
levels, and these same studies suggest that IL-6 is secreted from the
aneurysm since its level directly correlates with aneurysm surface
area.50 Second, downstream IL-6 signaling effectors, such as JNK, are
activated in AAA samples compared to controls.51 Further, meta-
analysis of five different studies showed that the rs2228145 minor
(C) allele within the IL-6R gene (as well as proxy SNPs rs7529229 and
rs4129267) was associated with lower AAA risk (OR, 0.84).49
rs2228145 is a nonsynonymous variant located in exon 10 of the IL-
6R gene that results in substitution of asparagine for alanine at amino
acid position 358, which dampens signaling through IL-6R in
lymphoblastoid cells. Furthermore, IL-6R inhibition with MR16-1
reduced aortic diameter in mice compared to an IgG negative control
antibody when measured at 6 weeks after CaCl2 treatment
(AAA diameter 0.92 mm vs 1.08 mm, respectively).52 Additionally,
angiotensin II-induced AAA formation was reduced in Apo E −/− mice
by inhibiting the IL-6 effector JAK with SP600125, providing further
evidence that the IL-6 pathway modules aneurysm formation.53,54
Finally, rs10757278 (G variant) is located within the 9p21 locus
encoding CDKN2A/B and is thought to influence cardiovascular dis-
ease risk through an inflammatory-mediated process.55 Although this
locus has a well-established link to coronary artery disease, myocardial
infarction, and type 2 diabetes, the association with AAA was inde-
pendent of these.56,57 Finally, rs10757278 is also associated with
peripheral artery disease and intracranial aneurysm, but the strongest
association is with AAA (OR, 1.32).58
2.2.3 | Lipid metabolism and cell survival
Hyperlipidemia is a major risk factor for atherosclerosis, which is
found in many patients with AAAs.59 Not surprisingly, several DNA
variants affecting lipid metabolism influence AAA risk. One of these,
rs6511720, is located within the first intron of the LDLR gene
and was identified in a large GWAS of UK, New Zealand, and
Australian populations.60 The rs6511720 minor (A) allele, which is
associated with decreased risk of AAA, is located within a DNase-
hypersensitivity site (DHS) marked by H3K27 acetylation in multiple
cell types (UCSC Genome Browser). DHS are areas of open chromatin
that are accessible to key transcription factors and, along with H3K27
acetylation, often mark key promoter and enhancer regions that drive
gene expression.61,62 Thus, given its location in a putative regulatory
region, rs6511720 may lead to allele-specific changes in LDLR gene
transcription, although mechanistic studies testing this are necessary.
Changes in LDLR expression likely underlie AAA risk, especially given
that the LDLR knockout mouse develops AAA.63
The rs1466535 major (C) allele, located in the second intron of the
LRP1 gene, is associated with increased AAA risk.64-66 Aortic tissues
from patients harboring the rs1466535 major (C) allele had increased
LRP1 expression compared to the minor (T) allele, and the C allele
exhibited increased transcription activity and increased SREBP-1 bind-
ing compared to the T allele.67 Interestingly, LRP1 is a large endocytic
transmembrane receptor that structurally resembles the LDL binding
domains of LDLR, and several studies indicate that LRP1 plays a protec-
tive role against AAA formation.68 First, selective LRP1 knockout in vas-
cular smooth muscle cells promotes AAA formation in mice.69 Second,
LRP1 limits protease activity thereby preventing elastin fiber degrada-
tion in the vessel wall.70,71 While Bown et al found that LRP1 expres-
sion was higher for the CC (risk) genotype compared to TT (control)
genotype, another much smaller study in Chinese patients found that
LRP1 expression is lower in AAA tissue compared to healthy tissue.67,72
These conflicting results may be due to differences in sample collection
or may represent time-dependent differences in LRP1 expression.
Finally, rs7025486 is located in the first intron of the DAB2IP
gene, and the A allele is associated with increased AAA risk.73 DAB2IP
is expressed in several tissues including heart, endothelium, vascular
smooth muscle, as well as several cancer cell lines, and is a member of
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the RasGAP family of proteins critical for TNF-induced ASK1/JNK
activation.74,75 DAB2IP inhibits cell survival and proliferation by
downregulating PI3K-Akt and Ras signaling pathways, ultimately lead-
ing to increased apoptosis.76 Another, yet less-studied, function of
DAB2IP is its ability to regulate lipid droplet metabolism by inhibiting
the activity of the lipid trafficking protein, RAB40C.77 RAB40C is
required for lipid droplet metabolism, since CRISPR-Cas9-mediated
deletion of RAB40C causes lipid over-accumulation, while RAB40C
overexpression reduces lipid droplet accumulation in hepatocytes.
However, in the presence of DAB2IP, RAB40C's effects on lipid
processing are reduced. Notably, rs7025486 genotype demonstrates
tissue-specific effects on DAB2IP expression.73
2.2.4 | Cell adhesion
Another AAA-associated SNP, rs7635818, is located approximately
200 kb upstream of the CNTN3 transcription start site.78 The CNTN3
gene encodes contactin-3, which is a lipid-anchored cell adhesion protein
expressed in aortic tissue. While the contactin family has been exten-
sively studied in the nervous system, only one study to date has exam-
ined contactin-3 specifically.79,80 The C minor allele is associated with
increased AAA risk and shows an even stronger association with AAA in
smokers compared to nonsmokers (OR, 1.80 vs 1.56, respectively).80
Given its location in the 50 proximal gene region, rs7635818 may effect
CNTN3 transcription; however, no studies to date have examined the
relationship between rs7635818 genotype and CNTN3 expression.
2.2.5 | Vascular development and EC/SMC
differentiation
rs1795061 is located about 40 kb upstream of the SMYD2 transcription
start site and also associated with AAA.32 Transcription factor binding
sites have been identified within the SMYD2 eQTL locus, indicating that
other SNPs in linkage with rs1795061 may affect transcription factor
binding and SMYD2 expression.81 The SMYD proteins are a family of
lysine methyltransferases that play fundamental roles in regulating skele-
tal and cardiac morphogenesis.82 One member of this family, SMYD2,
methylates several histone and nonhistone targets, including BMPR2,
Hsp90, and p53.83-85 SMYD2 has been implicated in cancer cell prolifer-
ation and plays a role in embryonic stem cell differentiation.86,87 New
evidence suggests that SMYD2 make be linked to AAA pathogenesis. In
particular, one report identified several hypomethylated CpG islands
within the SMYD2 promoter in AAA samples, which had decreased
SMYD2 expression compared to healthy control samples.88 Whether or
not rs1795061 or alternate SNPs in this same locus affect DNA methyla-
tion is yet to be determined. However, this is an attractive hypothesis
since decreased SMYD2 expression has been described in cardiovascular
disease and inflammation.89
The same study by Jones et al. identified the AAA-risk variant,
rs2836411, which is located at 21q22.2 in an intronic region within the
ERG gene.32 The rs2836411 minor (T) allele is associated with increased
AAA risk in several populations. ERG is a transcription factor expressed
in both hematopoietic and endothelial cells and mediates several key
processes of vascular development, including endothelial specification,
angiogenesis, and vessel stability.90 Not surprisingly, ERG is most highly
expressed in arterial tissues, as listed in the GTEx database, and it is an
important upstream regulator of VEGF-inducible genes essential for
angiogenesis and vasculogenesis.91 One potential mechanism linking
ERG to AAA formation is the observation that angiogenesis is increased
in the aneurysm wall.92 Furthermore, ERG binding to a critical regulatory
enhancer in the DLL4 gene mediates arterial specification.93 Future stud-
ies should determine if ERG expression, rs2836411 genotype, and AAA
risk are all associated with each other.
2.2.6 | Additional variants in genes with unknown
function
The rs9316871 (G) minor allele is protective against AAA.32 Interest-
ingly, the closest nearby gene to rs9316871 is LINC00540, which is a
long noncoding RNA (lncRNA) with no known function to date. How-
ever, Jones et al found that this variant was associated with another
nearby gene, FGF9, the expression of which was increased in AAA tis-
sue relative to controls.94 Briefly, FGF9 is a mitogen secreted from
bone marrow cells that exerts several functions on vascular SMC,
including stimulating SMC investment of angiogenic vessels as well as
driving SMC proliferation after arterial injury.94,95 Although allele-
specific differences in FGF9 expression may link rs9316871 to AAA
risk, it is also possible that this SNP locus affects LINC00540 levels,
perhaps through altering its stabilization since the variant is located
near the 30 UTR of LINC00540. While these are tempting hypothesis,
it is important to emphasize that SNP proximity does not necessarily
predict a functional association on nearby genes. Alternative explana-
tions include linkage of rs9316871 with functional SNP(s) elsewhere
in the genome or perhaps rs9316871 affects gene architecture via
long-range interactions with other gene regions.
3 | LIMITATIONS OF GWAS
Although excellent tools for identifying variants implicated in disease,
GWAS have several limitations that should be kept in mind in order to
put these results in the appropriate clinical context. First, given the high
number of individual variants being tested, the possibility that an associa-
tion is actually due to chance is quite high. Second, not all variants identi-
fied are causal and it can take great effort to identify functional SNPs.
GWAS also fail to capture epistasis between loci, or to what degree
interactions between several variants or gene regions influence disease.
One of the biggest arguments is that GWAS have limited clinical predic-
tive value and applicability. The latter is due to both the small effect sizes
and heritability of the majority of associations, which could be offset eas-
ily by environmental contributions. While one hope of GWAS is to iden-
tify individuals at risk for disease, this is not as valuable if no
personalized treatment exists. Additionally, many of the GWAS-related
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SNPs are at such low allele frequencies that large numbers of individuals
would need to be tested to identify a single rare variant, calling into
question the practicality of such a test for screening purposes. Finally,
except for rare instances, the exact relationship between the vast major-
ity of GWAS associations and AAA risk remains unclear, and relatively
very few associations out of all identified are actually causal.
4 | EPIGENETIC REGULATION OF AAAS
While AAA pathogenesis is influenced by genetic mutations, a number of
epigenetic factors also affect aneurysm formation. Epigenetic mechanisms
cause dysregulated expression of aneurysm genes without significant
sequence variation, as is the case for genetic causes of disease. Epigenetic
modes of regulation include microRNAs, long noncoding RNAs, histone
modifications, and DNA methylation, all of which modulate gene transcrip-
tion (Figure 1). Several of these epigenetic changes have an established
role in AAA pathogenesis; however, in most cases the connection
between epigenetic regulation and aneurysm development is less clear.
While genetic and epigenetic mechanisms are discussed separately, the
two may interact to facilitate higher order gene regulation. In other words,
are the epigenetic factors identified independent of SNPs that affect
expression of known aneurysm genes? This is an important question not
addressed by most epigenetic studies or GWAS that should be considered
in the context of the discussions throughout this manuscript.
4.1 | NONCODING RNAs ASSOCIATED
WITH AAAs
4.1.1 | MicroRNAs
MicroRNAs (miRNAs) are short, single-stranded RNA molecules com-
prised of 17 to 23 bases that exert a variety of cellular functions by
directly regulating gene expression.96,97 In general, miRNAs negatively
regulate gene expression either by degrading mRNA or inhibiting
translation. In either case, the mature miRNA pairs with a highly con-
served “seed” sequence within the 30 UTR of the target gene. Impor-
tantly, a single miRNA may regulate several genes; thus, most miRNAs
are involved in complex regulatory networks of gene expression.98
Several miRNAs play a role in AAA development pathogenesis. By far,
the miRNA-29 family has one of the strongest associations with AAA,
and different studies show that miRNA-29 promotes AAA formation
by modulating the fibrotic response and ECM in vitro and in vivo.99
Validated targets of miRNA-29b include several collagen types in
aorta including COL1A1, COL2A1, COL3A1, and COL5A1.100,101
miRNA-29 also targets ECM genes, ELN and FBN1, and members
of the MMP family.101,102 Maegdefessel et al found that miRNA-29b
overexpression enhanced aneurysm expansion and rupture rate,
which was also associated with decreased expression of fibrotic
genes, including COL1A1, COL3A1, and ELN.99 Conversely, inhibiting
miRNA-29b with anti-miR-29b decreased AAA rate and increased
fibrotic gene expression. Finally, miRNA-29b levels are downregulated
at different timepoints throughout AAA development in mice and
associated with increased aortic collagen gene expression—protective
changes thought to limit AAA expansion.99
Another miRNA that appears to affect AAA development by regu-
lating ECM turnover is miR-181b. miR-181b stimulates ECM degrada-
tion by inhibiting TIMP3, which normally prevents ECM
breakdown.103 Accordingly, miR-181b antagonism inhibits ECM rem-
odeling and AAA formation. However, miR-181b has positive and
negative effects on atherosclerosis, which makes attempt at therapy
challenging since anti-miR targeting could lead to off-target effects.
TIMP3 expression is also negatively regulated by miR-205, which
leads to decreased ECM breakdown by directly targeting TIMP3.104
With less ECM degradation, miR-205 would hypothetically stabilize
the aneurysm. Similarly, miR-195 regulates ECM dynamics by directly







































F IGURE 1 Epigenetic factors including
noncoding RNAs, histone modifying agents, and
changes in DNA methylation associated with
AAA. *Most LncRNAs described in this review
have not been validated as either protective or
causative in relation to AAA. Therefore, the
associations listed for LncRNAs in the above
diagram are hypothesized based on their reported
effect
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reduced in AAA samples but increased in a preclinical mouse model
of AAA.
Several miRNAs affect AAA development by modulating differ-
ent inflammatory components. First, by directly targeting Chi311,
miR-24 limits inflammation by inhibiting macrophage recruitment
and survival as well as blocking production of cytokines IL-8 and
CCL2 by SMCs and macrophages.106 Another important microRNA,
miR-33, modulates the inflammatory response, but does so by
inhibiting the pro-inflammatory cholesterol transporter ABCA1.107
In both the CaCl2 and Ang II mouse models of AAA, inhibiting miR-
33 prevents AAA formation through upregulated ABCA1 expres-
sion. Global loss of function experiments as well as macrophage-
specific deletion of miR-33 both inhibited atherogenesis and
related-sequelae, suggesting that the effects of miR-33 on AAAs
are mediated by macrophages.
Next, the miRNA-143/145 cluster has been implicated in vascular
smooth muscle biology, and in particular, induces a differentiated,
contractile smooth muscle cell phenotype.108 While studies are lac-
king regarding the exact effect of this miRNA cluster on aneurysm
pathophysiology, it is reasonable to hypothesize it may stabilize the
AAA since it inhibits SMC phenotypic modulation, which often occurs
during AAA expansion. However, as noted, this miRNA set has been
implicated in other vascular diseases and is not specific for AAA.
4.1.2 | Long noncoding RNAs
Overall less is known about the exact mechanisms by which long non-
coding RNAs (lncRNAs) regulate gene expression compared to
miRNAs, especially in the setting of AAAs. LncRNAs are >200 nucleo-
tides in length and regulate gene expression by affecting overall gene
architecture, specifically by acting as scaffolds for gene regions and
transcription factors. In this manner, lncRNAs can guide activator and
repressor transcriptional complexes to key regulatory gene regions to
modulate overall gene transcription. LncRNAs can also sponge cyto-
plasmic miRNAs to inhibit their function on transcription. One of the
first AAA-associated lncRNAs identified was H19, which was
upregulated in Ang II- and pancreatic elastase mouse models of AAAs
compared controls.109 In this same study, inhibiting H19 prevented
AAA growth in both described models, indicating that H19 played a
positive role in aneurysm pathogenesis. In support of this, H19 was
upregulated in human AAA and seems to promote aneurysm develop-
ment by increasing vascular inflammation.110
Another lncRNA that has been implicated in AAA pathogenesis is
PVT1, which appears to enhance AAA formation.111 PVT1 levels are
upregulated in AAA tissues from patients as well as from ApoE −/−
mice infused with Ang II, and stimulation of vascular smooth muscle
cells with Ang II in vitro increased PVT1 expression. Overexpression
of PVT1 in Ang II-infused mice enhanced vascular smooth muscle cell
apoptosis, ECM degradation (as measured by increased MMP-2 and
MMP-9 expression), and phenotypic switching of smooth muscle cells
(decreased expression of smooth muscle alpha-actin). Further, both
PVT1 knockdown in vitro and silencing PVT1 in vivo using lentiviruses
blocked these biochemical effects of aneurysm pathogenesis, provid-
ing strong evidence that PVT1 promotes AAA formation.
Initially identified as a long noncoding RNA in LDS patients,
AK056155 is increased nearly 2-fold in patients with AAAs compared to
controls.112 Further, since variants in several components of the TGFβ
pathway underlie AAA formation found in LDS, the authors of this study
tested the relationship between TGFβ and AK056155. Interestingly,
TGFβ increased AK056155 expression in a dose-dependent manner, an
effect that was found to be downstream of PI3K/AKT signaling. This lat-
ter finding is important because AK056155 expression was increased by
the PI3K inhibitor, LY294002, highlighting the therapeutic potential of
modulating AK056155 levels in the treatment of AAAs.
Several lncRNAs that affect SMC function and differentiation
have been identified, and it is reasonable that some of these may also
regulate AAA formation since SMC physiology is perturbed in
AAAs.113 One of the first studies to characterize such lncRNAs was
by Leung et al, who identified 29 vascular SMC-enriched lncRNAs
that were associated with transcriptionally active chromatin and also
differentially regulated by Ang II.114,115 One of these, lnc-Ang362, is
increased in response to Ang II stimulation and is physically located
close to the Ang II-responsive miRNA genes, mir-221 and mir-222,
which upregulate vSMC proliferation and neointimal hyperplasia.116
Additionally, very recently, Jeong et al found that the long noncoding
RNA Lrrc75a-as1 was enriched in vascular SMC and inhibited vascular
calcification, a well-known feature of AAAs.117
SMILR was identified in a screen of lncRNAs whose expression
was influenced by IL-1alpha and PDGF, cytokines that regulate
vSMC migration and proliferation.118 SMILR knockdown reduced
vSMC proliferation, and its expression was increased in unstable
atherosclerotic plaques from human patients. Another lncRNA,
SENCR, is enriched in vascular endothelial and smooth muscle cells
and inhibits expression of migratory genes while upregulating
expression of contractile genes (eg, myocardin) required for SMC
differentiation.119 Finally, GAS5 inhibits TGFβ/Smad3-dependent
SMC differentiation by scavenging Smad3 via Smad binding ele-
ments within the RNA strand.120 Thus, based on its ability to down-
regulate SMC differentiation, it is reasonable to hypothesize that
this lncRNA promotes AAA pathogenesis.
The transcription factor myocardin is a potent regulator of SMC
gene expression. In an attempt to identify lncRNAs involved in regu-
lating myocardin-induced SMC differentiation, Zhao et al. performed
RNA sequencing in human coronary SMC overexpressing myocardin
and found that one lncRNA in particular, which they termed
MYOSLID, was activated by myocardin.121 Specifically, MYOSLID was
a direct target of myocardin and SRF, and functional experiments rev-
ealed that MYOSLID promoted the mature smooth muscle phenotype
and SMC differentiation. Opposite to the effect of MYOSLID, the
recently identified NEAT1 promotes the immature, proliferative SMC
phenotype, while inhibiting expression of mature, contractile genes by
sponging the chromatin modifier WDR5 from key SMC gene loci.122
Further, NEAT1 knockout mice displayed decreased neointima forma-
tion after vascular injury. As described earlier, the 9p21 genetic risk
locus is associated with several vascular diseases, including AAA.64
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While this locus spans several genes, one of the risk polymorphisms is
located in the ANRIL gene, which encodes a long noncoding RNA that
has been implicated in AAA development. ANRIL is transcribed anti-
sense to the genes CDKN2A and CDKN2B, and several studies indi-
cate that ANRIL modulates SMC proliferation by regulating expression
of these genes.123
4.2 | Histone modifications
Histone modifications at key promoter and enhancer gene regions are
associated with gene activation or repression, depending on the spe-
cific histone signature, and histone acetylases, deacetylases, and met-
hyltransferases all carry out these modifications. H3K4me3 marks
active promoters, H3K4me1 active enhancers, and H3K27ac marks
both active promoters and enhancers. In contrast, H3K27me3 is
found at sites of inactive chromatin. Combinations of these histone
marks lead to changes in chromatin structure that either facilitates or
prevents key transcription factor binding, thereby activating or repre-
ssing gene transcription. Furthermore, unique histone signatures dis-
tinguish diseased vs healthy tissues.124,125
Recently, it has been hypothesized that these epigenetic modifi-
cations may also underlie AAA pathogenesis. For example, acetylation
of H3K9, H3K14, and H3K18 was increased in AAAs compared to
healthy samples.126 In a different study, expression of several histone
deacetylases (HDAC) was increased in samples from AAA compared
to healthy donors, and Ang II infused ApoE −/− AAA mouse models
also had higher HDAC expression than controls.127 Interestingly, in
this same study, class I and IIa HDAC inhibition with MS-275 and
MC-1568, respectively, improved survival and decreased AAA forma-
tion in mice, which was shown in part to be due to decreased MMP-2
and -9 activity after HDAC inhibition. This is not the first report of
HDAC inhibition reducing AAA pathogenesis: another HDAC inhibi-
tor, MCT-1, reduced AAA incidence in Ang II infused Apo E −/−
mice.128 Furthermore, MCT-1 reduced expression of MMP-2 in
vSMCs and both MMP-2 and MMP-9 in aortic tissue. These afore-
mentioned studies suggest that histone acetylation patterns located
within the MMP-2 and MMP-9 genes modulate AAA formation,
and that targeting histone acetylation at these specific loci may limit
AAA expansion.
Histone modifications in immune cells module AAA pathogenesis;
however, the specific direction of effect is less understood. Expres-
sion of histone acetyltransferases including GNAT, p300, and MYST
was significantly higher in T cells and endothelial cells from AAA vs
healthy tissue samples.126 However, HDAC1 mRNA levels were lower
in T cells collected from patients with AAA compared to controls,
while H3 and H3K14 acetylation in T cells was higher than in con-
trols.129 This is in contrast to findings from a different group, who
showed that HDAC1 and HDAC5 mRNA levels were higher in T regu-
latory cells collected from patients with AAA vs controls.130 One pos-
sible explanation for this finding is that levels of acetylation and
HDAC expression change throughout the course of disease. Another
possibility is that T regulatory cells as a subset may be marked by
unique histone acetylation patterns that do not reflect the larger
peripheral T cell population.
4.3 | DNA methylation
DNA methylation is a heritable epigenetic modification that occurs
at CpG islands within gene promoters, resulting in transcriptional
silencing, and is carried out on cytosines by DNA met-
hyltransferases (DNMTs). While the largest effect of DNA methyla-
tion on AAA risk is due to transcriptional dysregulation of key
aneurysm-associated genes, few studies actually implicate AAA
genes as targets. One explanation for this could be decreased sen-
sitivity of current panels or exclusion of some of these genes on
existing panels. Additionally, it is possible that DNA methylation is
a sensitive epigenetic change that is not recapitulated completely
by current models. Finally, analysis of vascular cell types including
endothelial, smooth muscle, or adventitial cells may yield more
aneurysm-specific targets, since the studies that do exist have
focused on DNA methylation in T cells. Increasing evidence sug-
gests that T cell dysfunction, particularly decreased suppressive
effects of CD4 + CD25+ T regulatory cells, drives AAA develop-
ment.131 Part of this change arises from epigenetic alterations like
DNA methylation, which is significantly decreased in T cells from
patients with AAA compared to healthy controls.132 Similarly, DNA
methylation in T cells was negatively correlated with AAA diameter.
Expression of both DNMT1 and methyl-CpG-binding domain
2 (MBD2), both involved in mediating DNA methylation and tran-
scriptional repression, was also decreased in isolated T cells from
AAA samples relative to controls. In contrast, Xia et al showed that
T regulatory cells from AAA patients have higher levels of DNMT1,
DNMT3A, and MBD2 compared to controls.130
Elevated homocysteine levels have long been associated with
vascular disease, and its relation to AAA has also been reported previ-
ously.133,134 Additionally, several DNA variants within genes involved
in homocysteine metabolism have been linked to AAA and/or aortic
diameter in the human population. These include rs8003379 in
MTHFD1, rs326118 in MTRR, rs202680 in FOLH1, rs2853523 in
MTR, and rs1801133 and c.677C > T in MTHFR.135,136 It has been
suggested that hyperhomocysteinemia may underlie AAA develop-
ment through cell type-specific hypomethylation.137 However, more
studies are needed to test this hypothesis directly.
While DNA hypomethylation is associated with AAA, as noted
above, several additional studies indicate that hypermethylation at
specific gene promoters is also linked with AAA development. One
recent study addressed this by assessing global methylation in periph-
eral blood mononuclear cells from patients with AAA and compared
these methylation patterns to healthy controls.88 This study showed
that AAA DNA was hypermethylated and correlated with aneurysm
size. Specific CpG sites of hypermethylation occurred in IL6R and
ERG, while CpG hypomethylation was found in SERPINB9 and
SMYD2. Further, methylation of the SMYD2 promoter was directly
correlated with SMYD2 expression, which was decreased in AAA
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samples. From this study and others, it is clear that unique DNA meth-
ylation patterns across multiple genes influence AAA risk.
5 | CONCLUSION
Numerous genetic and epigenetic factors may influence AAA risk. In
addition to Mendelian, single-gene causes, numerous DNA variants
(the majority of which are in noncoding regions) with a potential link
to AAA in humans have been identified in GWAS and are outlined
here. Importantly, most GWAS SNPs do not affect AAA risk, and
these should be differentiated from the more rare, true pathogenic
variants. Accordingly, it is necessary to determine which SNPs out of
the many identified are functional variants. Coding variants can affect
protein function while others in promoter-enhancers may affect gene
expression, and such changes in protein activity or transcription,
respectively, modify AAA risk. In vitro and in vivo experiments are
required to determine if the variants described above are functional.
GWAS for AAA have identified SNPs in genes with previously
unknown function. In an effort to identify how such variants affect
AAA risk, studies have helped uncover how gene function regulates
AAA pathogenesis. Future research should be geared toward cell
type-specific mechanisms of disease, since a significant number of
reports analyze whole aortic tissue rather than specific cell types from
aneurysm samples.
Several microRNAs and long noncoding RNAs have been identi-
fied that regulate expression of aneurysm-related genes and play a
role in AAA pathogenesis. Accordingly, some of these noncoding
RNAs may serve as therapeutic targets for decreasing AAA progres-
sion. Similarly, dynamic chromatin states regulate expression of genes
known to play a role in aneurysm development. Such functional states
are also modulated by histone modifications and DNA methylations,
which vary in AAA, and additional work should focus on the specific
gene loci where these modifications occur.
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